News & Presentations

UPCOMING EVENTS

There are currently no events to display.

CORPORATE PRESENTATIONS

Date Title Documents

Corporate Presentation – May

Topline Results from Rhopressa® (netarsudil ophthalmic solution) 0.02% Phase 4 Multi-center Open-label Study (MOST)

AR-13324-CS208 Japan Phase 2 Study Topline Results

News Releases

Date Title and Summary Additional Formats
Toggle Summary Aerie Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Business Update
Conference Call and Webcast Today, May 6 th , at 5:00 p.m. ET DURHAM, N.C. --(BUSINESS WIRE)--May 6, 2020-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of
View HTML
Toggle Summary Aerie Pharmaceuticals to Present at the Bank of America Securities 2020 Healthcare Conference
DURHAM, N.C. --(BUSINESS WIRE)--May 5, 2020-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases and
View HTML
Toggle Summary Aerie Pharmaceuticals to Announce First Quarter 2020 Financial Results and Host Conference Call on Wednesday, May 6, 2020
DURHAM, N.C. --(BUSINESS WIRE)--Apr. 29, 2020-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases
View HTML
Toggle Summary Aerie Pharmaceuticals Provides 2020 Company and Guidance Update Associated with COVID-19
DURHAM, N.C. --(BUSINESS WIRE)--Apr. 9, 2020-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases
View HTML
TOP